What Kills Fungus in the Sinuses: Surgery vs. Antifungals

Surgery does most of the heavy lifting for nearly every form of fungal sinusitis, but the role of antifungal drugs varies dramatically depending on which type you have. A compact fungal mass lodged in one sinus can be cured by endoscopic removal alone, with no antifungals at all. An allergic reaction to fungal debris in the sinuses relies more on steroids than on antifungals. And a life-threatening invasive infection demands both aggressive surgical debridement and potent intravenous antifungal drugs simultaneously. The real answer to “what kills fungus in the sinuses” is that the category of disease dictates the weapon.

Not All Fungal Sinusitis Is the Same Disease

Fungal sinusitis falls into several distinct categories, and each behaves so differently that treatment for one would be inappropriate for another. The two broadest divisions are non-invasive and invasive. In non-invasive disease, the fungus sits inside the sinus cavity but does not penetrate the tissue lining. In invasive disease, the fungus burrows into tissue, blood vessels, and sometimes bone. Within those two camps, further subdivisions matter. Non-invasive disease includes fungus balls (a dense clump of fungal material, usually in the maxillary or sphenoid sinus) and allergic fungal rhinosinusitis, or AFRS (an allergic overreaction to fungal proteins, often with thick mucus and nasal polyps). Invasive disease can be acute, progressing in days to weeks and potentially fatal, or chronic, smoldering over months. Each of these has a different relationship with surgery and antifungal medication.

Fungus Balls and Why Surgery Alone Cures Them

A fungus ball is exactly what it sounds like: a dense, tangled mass of fungal hyphae that accumulates in a sinus, usually without invading the surrounding tissue. The standard treatment is functional endoscopic sinus surgery, where a surgeon widens the natural opening of the affected sinus and removes the fungal material. In a review of 175 cases, all maxillary, sphenoidal, and ethmoidal fungus balls were treated exclusively this way, with only one true local failure and six cases of persistent fungal material over a five-year follow-up. No antifungal medication was required.¹

A systematic review and meta-analysis of fungus ball treatment confirmed a treatment success rate of about 98%, and neither sinus flushing during surgery nor postoperative antibiotics improved outcomes.² Another study of 40 cases reached the same conclusion: complete endoscopic removal is the treatment of choice, recurrence is rare, and neither systemic nor topical antifungal therapy is necessary afterward.³

The logic here is straightforward. The fungus ball is not invading tissue, so there is no deep infection to chase with drugs. Once the clump is physically removed and the sinus can drain and ventilate normally again, the problem is solved. Postoperative care typically involves saline rinses and a short course of topical nasal steroids to manage inflammation.

Allergic Fungal Rhinosinusitis and the Steroid-Versus-Antifungal Debate

AFRS is a different beast. The fungus itself is not invading tissue, but the immune system mounts an intense allergic reaction to fungal proteins sitting in the sinus mucus. This triggers a cascade of inflammation dominated by eosinophils, thick “allergic mucin,” and often dramatic nasal polyps that can erode bone over time.⁴ The inflammation, not the fungus, is the primary driver of symptoms and tissue damage.

Surgery is still the first step. Endoscopic sinus surgery removes the allergic mucin, polyps, and fungal debris, and opens the sinuses for ventilation and topical treatments. But because AFRS is fundamentally an immune-driven disease, simply removing the fungal material does not stop the underlying allergic process. Recurrence rates are high compared to fungus balls. Research describes AFRS as having elevated postoperative recurrence and a poorer prognosis than other subtypes of chronic rhinosinusitis with nasal polyps.⁵

After surgery, the question becomes what to use to prevent recurrence: oral steroids, the antifungal itraconazole, or both. The evidence is genuinely mixed, which is why clinicians disagree on this. One randomized trial comparing steroids against itraconazole after surgery found that steroids outperformed itraconazole on most endoscopic and symptom scores, though the difference in recurrence rates (about 24% for steroids versus 44% for itraconazole) did not reach statistical significance.⁶ Another trial reached a somewhat different conclusion, reporting that itraconazole provided better symptomatic relief and endoscopic clearance, even though the statistical difference between groups was again non-significant.⁷

A third study found that combining steroids with itraconazole after surgery reduced recurrence to about 10%, compared with 25% for steroids alone, with significantly better symptom scores in the combination group.⁸ The upshot is that steroids are the workhorse for post-surgical AFRS management, and itraconazole may add benefit as a supplementary therapy rather than a replacement. The antifungal is not “killing the infection” in the way you might expect; it is reducing the fungal burden so the allergic cascade has less to react to.

Acute Invasive Fungal Sinusitis and the Race Against Time

Acute invasive fungal sinusitis is the most dangerous form and represents a genuine medical emergency. It almost exclusively strikes people with severely weakened immune systems: patients undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, people with uncontrolled diabetes (especially in diabetic ketoacidosis), and those with HIV.⁹ The fungi responsible, often species like Aspergillus or Mucor, invade blood vessels, cause tissue death, and can spread to the orbit or brain within days.¹⁰

Here, neither surgery nor antifungals alone is sufficient. Treatment requires urgent surgical debridement to cut away all dead and infected tissue, combined with aggressive intravenous antifungal therapy. The traditional drug is amphotericin B (specifically the liposomal form, which is less toxic to the kidneys). A systematic review of published evidence found that patients who had surgery and received liposomal amphotericin B had improved survival odds, while advanced age and spread to the brain were negative prognostic factors.¹¹

Multiple surgeries are often necessary. In one series of 150 operated patients, about 15% of survivors needed revision debridement for progressive or recurrent disease, and roughly 13% died during treatment.¹² When the infection has already reached the brain, aggressive debridement of the intracranial disease appears to matter enormously. One study found a 93% reduction in the risk of death when intracranial debridement was performed, compared with patients who did not have that component of surgery.¹³

The third critical pillar of treatment is reversing the underlying immune compromise: controlling blood sugar in diabetic ketoacidosis, reducing immunosuppressive medication where possible, or using growth factors to stimulate white blood cell recovery in chemotherapy patients. Without restoring immune function, neither surgery nor drugs can outpace the infection.

Chronic Invasive Fungal Sinusitis and Long-Term Antifungal Use

Chronic invasive fungal sinusitis is rarer and more indolent. It develops over weeks to months, sometimes in patients who are only mildly immunocompromised or even apparently healthy. Because the disease progresses slowly, the surgical approach can be more conservative than in the acute form, relying on endoscopic techniques rather than radical open procedures. However, these patients still need long-term antifungal therapy. A case series at one center treated every patient with endoscopic surgery and prolonged antifungal treatment, and all were free of invasive disease at their last follow-up.¹⁴

The antifungal of choice has been shifting. Amphotericin B, which must be given intravenously and has significant kidney toxicity, was long the default. Voriconazole, an oral antifungal with better tolerability, has shown promise as a new standard option. A report of three cases of chronic invasive fungal sinusitis treated with surgery and voriconazole showed good responses in all patients.¹⁵ The ability to take voriconazole orally for months makes it far more practical for a disease that requires extended treatment.

Why Antifungal Drugs Struggle in the Sinuses

Across all types of fungal sinusitis, there is a pattern: antifungal drugs alone rarely solve the problem. Several factors explain this. One of the most important is biofilm formation. Fungi in the sinuses can form biofilms, structured communities encased in a protective matrix that acts as a physical barrier between the fungal cells and any drug attempting to reach them. This shielding effect allows fungi to persist even under maximal antifungal therapy.¹⁶ Surgery physically disrupts biofilms in a way that drugs cannot.

The delivery challenge compounds the problem. The sinuses are air-filled cavities lined with mucosa, and getting a drug to actually contact the fungal organism in meaningful concentrations is difficult. Topical antifungal rinses, which seemed like an intuitive solution, have not panned out. A Cochrane systematic review of topical and systemic antifungal therapy for chronic rhinosinusitis found that topical antifungals (mostly amphotericin B rinses) showed little or no benefit. Systemic antifungals performed no better and carried the added risk of liver toxicity.¹⁷

A small pilot trial did find that intranasal amphotericin B reduced mucosal thickening on CT and improved endoscopic scores compared to placebo over six months.¹⁸ But a subsequent larger randomized study found that nasal irrigation with amphotericin B after endoscopic sinus surgery provided no additional benefit over saline irrigation alone.¹⁹ The hopeful early results did not hold up. This is part of why surgery remains the foundation: it physically removes what drugs cannot easily penetrate.

What Surgery Actually Does at the Tissue Level

Understanding why surgery works so well requires looking at what happens to the sinus lining afterward. Endoscopic sinus surgery aims to widen the natural drainage pathways and remove diseased material while preserving as much healthy mucosa as possible. When the mucosa is conserved or only the surface is removed, ciliated cells regenerate within about six months.²⁰ Those cilia are the sinus’s self-cleaning system, sweeping mucus and trapped particles (including fungal spores) toward the natural ostium and out of the sinus.

Once ventilation is restored, mucociliary function recovers, though the timeline depends on how damaged the mucosa was before surgery. In sinuses with relatively mild disease, drainage returned to normal within about three weeks. In sinuses with more severe mucosal changes, function improved significantly but still had not reached normal levels at the same time point.²¹ The practical message: surgery restores the sinus’s ability to clear itself, which is a form of ongoing antifungal defense that no medication can replicate.

Getting the Diagnosis Right and Why Speed Matters

The treatment strategy depends entirely on what type of fungal sinusitis you have, which means accurate and fast diagnosis is crucial. Traditional fungal culture, where a tissue sample is placed on a growth medium and watched for days, has been the standard for identifying the responsible organism. But culture is slow and misses organisms more often than clinicians would like. A study comparing fungal PCR testing to conventional culture found that PCR had a positivity rate of about 37% versus roughly 14% for culture, and delivered preliminary results faster. PCR identified organisms that culture missed in about 15% of cases and changed the clinical plan in nearly 17% of reviewed patients.²²

Speed is most critical in acute invasive disease, where a few days of delay can mean the difference between salvageable and unsalvageable tissue. But even in non-invasive disease, knowing the specific fungal species can occasionally guide management. In one study of non-invasive fungal sinusitis, Aspergillus flavus was the most common species, followed by Penicillium and Candida species.²³ Different species have different susceptibility profiles, which matters most when you are choosing a systemic antifungal for invasive disease.

Children Versus Adults

Invasive fungal sinusitis is rare in children, but when it occurs, the underlying risk profile looks different. A comparison of pediatric and adult cases found that children were far more likely to have a blood cancer as the predisposing factor (about 59% versus 15% in adults). Children also tended to present with disease still confined to the sinuses, whereas adults more frequently had extension beyond. Despite these differences, there was no significant difference in mortality between the two age groups.²⁴ The treatment principles are the same: surgical debridement, systemic antifungals, and reversing immune compromise.

The Fungal Ecosystem Inside Your Sinuses

One reason the “kill the fungus” framing can be misleading is that fungal organisms are present in healthy sinuses. Everyone inhales fungal spores constantly. The question is not whether fungi are there but whether they are causing disease. Sequencing studies of the sinus microbiome have shed light on how the fungal community differs between people with AFRS and those with normal sinuses. In one analysis, the AFRS fungal community was dominated by Malassezia, Curvularia, and Aspergillus, while healthy sinuses were nearly exclusively colonized by Malassezia with virtually no Aspergillus or dematiaceous (dark-pigmented) fungi detected.²⁵

This finding reinforces the idea that in AFRS, the problem is partly which fungi are present and partly how the immune system responds to them. Eradicating all fungi from the sinuses is neither possible nor desirable. The goal of treatment is to remove the fungal burden that is provoking disease, restore normal sinus function so the body can manage routine fungal exposure on its own, and modulate the immune response when it is the source of the damage.

Experimental Approaches on the Horizon

For patients with chronic recurrent disease, especially those whose fungal sinusitis involves drug-resistant organisms or stubborn biofilms, conventional options sometimes fall short. One approach being explored is antimicrobial photodynamic therapy, which uses a light-activated photosensitizing agent to destroy bacteria, fungi, and biofilms inside the sinuses. Early research demonstrated that this technique could effectively treat polymicrobial, antibiotic-resistant organisms and biofilms in chronic sinusitis, and human clinical trials were being planned to assess safety and efficacy.²⁶ This is still early-stage work, but it represents a fundamentally different angle: rather than relying on a chemical to reach and kill the fungus, it uses light energy delivered directly to the sinus surface. Whether it becomes a practical clinical tool remains to be seen, but it speaks to the broader recognition that new strategies are needed for cases where surgery and drugs together are not enough.